CMPS COMPASS Pathways plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1816590 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.2%
TTM EPS YoY14.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-296.5%
ROA-68.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets72.6%
Debt / equity0.36x
Current ratio1.50x
Interest coverage-35.36x
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-23.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $23.46M | $29.18M | $26.48M | $29.91M | $27.32M | $30.32M | $30.88M | $32.14M |
| SG&A expense | $32.98M | $23.20M | $16.42M | $16.05M | $13.21M | $12.61M | $18.74M | $16.27M |
| Operating income | -$56.44M | -$52.37M | -$42.90M | -$45.95M | -$40.54M | -$42.93M | -$49.62M | -$48.41M |
| Interest expense | $1.50M | $1.48M | $1.47M | $1.14M | $1.10M | $1.15M | $1.12M | $1.13M |
| Pretax income | -$10.94M | -$253.46M | $91.19M | -$96.61M | -$137.95M | -$38.27M | -$17.51M | -$42.31M |
| Income tax | -$1.11M | $331,000 | -$11,000 | -$2.73M | -$230,000 | $137,000 | $354,000 | $1.02M |
| Net income | -$9.83M | -$253.79M | $91.20M | -$93.88M | -$137.72M | -$38.40M | -$17.86M | -$43.33M |
| EBITDA | -$56.44M | -$52.37M | -$42.90M | -$45.95M | -$40.52M | -$42.77M | -$49.58M | -$48.36M |
| EPS (basic) | -0.07 | -1.88 | 0.71 | — | -1.44 | -0.41 | -0.20 | — |
| EPS (diluted) | -0.31 | -1.88 | -0.30 | — | -1.44 | -0.41 | -0.24 | — |
| Weighted avg. shares (diluted) | 162.57M | 135.04M | 130.27M | — | 95.34M | 93.34M | 98.64M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $443.98M | $433.30M | $466.01M | $149.61M | $185.94M | $221.88M | $260.11M | $165.47M |
| Current assets | $487.55M | $475.67M | $510.87M | $191.49M | $242.39M | $276.40M | $305.47M | $201.29M |
| PP&E, net | — | — | — | — | — | — | — | $189,000 |
| Total assets | $519.10M | $504.56M | $531.74M | $210.35M | $255.61M | $293.54M | $319.13M | $213.67M |
| Current liabilities | $325.86M | $367.29M | $153.80M | $247.79M | $197.45M | $31.33M | $30.00M | $34.02M |
| Short-term debt | $1.43M | $0 | $0 | $17.52M | $12.67M | $7.98M | $8.99M | $5.51M |
| Long-term debt | $49.56M | $50.73M | $50.48M | $14.11M | $18.60M | $22.95M | $21.55M | $24.65M |
| Total debt | $50.99M | $50.73M | $50.48M | $31.63M | $31.27M | $30.93M | $30.54M | $30.16M |
| Total liabilities | $377.03M | $420.03M | $205.05M | $263.20M | $218.02M | $130.98M | $123.67M | $58.97M |
| Shareholders' equity | $142.07M | $84.53M | $326.69M | -$52.85M | $37.59M | $162.56M | $195.47M | $154.69M |
| Net debt | -$392.99M | -$382.57M | -$415.53M | -$117.97M | -$154.67M | -$190.95M | -$229.57M | -$135.31M |
| Shares outstanding | 141.68M | 135.72M | 134.92M | 96.09M | 96.00M | 93.59M | 92.85M | 68.55M |
| Cash flow statement | ||||||||
| Operating cash flow | -$50.77M | -$40.31M | -$47.94M | -$37.79M | -$35.11M | -$38.69M | -$45.66M | -$41.76M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$41.76M |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $63.09M | $7.56M | $362.45M | $187,000 | $0 | $166,000 | $140.36M | $155,000 |
| Depreciation & amortization | $0 | $0 | $0 | $6,000 | $15,000 | $158,000 | $37,000 | $50,000 |
| Stock-based compensation | $4.45M | $4.03M | $2.90M | $2.85M | $3.21M | $3.60M | $3.94M | $4.49M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.